{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:33:17Z","timestamp":1788190397931,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018550","name":"Lowy Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010313","name":"Heidelberg Engineering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.xops.2025.101009","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T22:20:10Z","timestamp":1763590810000},"page":"101009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Results from a Phase I Extension Study of Ciliary Neurotrophic Factor in Patients with Macular Telangiectasia Type 2"],"prefix":"10.1016","volume":"6","author":[{"given":"Lawrence J.","family":"Singerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Hubschman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Y.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Egan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0397-8688","authenticated-orcid":false,"given":"Muna","family":"Bitar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Thomas M.","family":"Aaberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2025.101009_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.preteyeres.2012.11.002","article-title":"Macular telangiectasia type 2","volume":"34","author":"Charbel Issa","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.xops.2025.101009_bib2","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.ophtha.2020.03.040","article-title":"Macular telangiectasia type 2: visual acuity, disease end stage, and the MacTel area: MacTel project report number 8","volume":"127","author":"Heeren","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.101009_bib3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3109\/09286580903450361","article-title":"Baseline characteristics of participants in the natural history study of macular telangiectasia (MacTel): MacTel project report no. 2","volume":"17","author":"Clemons","year":"2010","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.xops.2025.101009_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ajo.2010.02.013","article-title":"The prevalence of macular telangiectasia type 2 in the Beaver Dam Eye Study","volume":"150","author":"Klein","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2025.101009_bib5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/IAE.0b013e3181bd2c71","article-title":"The prevalence estimates of macular telangiectasia type 2: the Melbourne collaborative cohort study","volume":"30","author":"Aung","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.xops.2025.101009_bib6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/09286586.2011.638744","article-title":"The prevalence of type 2 idiopathic macular telangiectasia in two African populations","volume":"19","author":"Sallo","year":"2012","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.xops.2025.101009_bib7","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/archopht.1982.01030030773010","article-title":"Idiopathic juxtafoveolar retinal telangiectasis","volume":"100","author":"Gass","year":"1982","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2025.101009_bib8","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.2147\/OPTH.S373538","article-title":"Macular telangiectasia type 2: a comprehensive review","volume":"16","author":"Kedarisetti","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.xops.2025.101009_bib9","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMoa1815111","article-title":"Serine and lipid metabolism in macular disease and peripheral neuropathy","volume":"381","author":"Gantner","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xops.2025.101009_bib10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/ng.3799","article-title":"Genome-wide analyses identify common variants associated with macular telangiectasia type 2","volume":"49","author":"Scerri","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.xops.2025.101009_bib11","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s42255-021-00361-3","article-title":"Serine biosynthesis defect due to haploinsufficiency of PHGDH causes retinal disease","volume":"3","author":"Eade","year":"2021","journal-title":"Nat Metab"},{"key":"10.1016\/j.xops.2025.101009_bib12","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1167\/iovs.15-16915","article-title":"Progression of vision loss in macular telangiectasia type 2","volume":"56","author":"Heeren","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.101009_bib13","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1167\/iovs.08-1749","article-title":"The National Eye Institute visual function questionnaire in the macular telangiectasia (MacTel) project","volume":"49","author":"Clemons","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.101009_bib14","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1167\/iovs.08-2032","article-title":"Reading performance is reduced by parafoveal scotomas in patients with macular telangiectasia type 2","volume":"50","author":"Finger","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.101009_bib15","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1097\/IAE.0000000000000082","article-title":"First symptoms and their age of onset in macular telangiectasia type 2","volume":"34","author":"Heeren","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.xops.2025.101009_bib16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/08820538.2021.1929347","article-title":"Long term follow-up of visual acuity and incidence of subretinal neovascularization in MacTel type 2 in 82 eyes","volume":"37","author":"Marsonia","year":"2022","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.xops.2025.101009_bib17","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027078","article-title":"Two years outcomes of treating full-thickness macula hole associated with idiopathic macular telangiectasia type 2 by internal limiting membrane inverted flap technique: case reports","volume":"100","author":"Nishiyama","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.xops.2025.101009_bib18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.preteyeres.2006.05.003","article-title":"M\u00fcller cells in the healthy and diseased retina","volume":"25","author":"Bringmann","year":"2006","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.xops.2025.101009_bib19","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1167\/iovs.10-6479","article-title":"Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment","volume":"52","author":"Talcott","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.101009_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100298","article-title":"Phase I NT-501 ciliary neurotrophic factor implant trial for primary open-angle glaucoma: safety, neuroprotection, and neuroenhancement","volume":"3","author":"Goldberg","year":"2023","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.xops.2025.101009_bib21","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1073\/pnas.1018987108","article-title":"Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration","volume":"108","author":"Zhang","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xops.2025.101009_bib22","doi-asserted-by":"crossref","first-page":"15715","DOI":"10.1523\/JNEUROSCI.2841-12.2012","article-title":"Conditional M\u00fcller cell ablation causes independent neuronal and vascular pathologies in a novel transgenic model","volume":"32","author":"Shen","year":"2012","journal-title":"J Neurosci"},{"key":"10.1016\/j.xops.2025.101009_bib23","first-page":"3292","article-title":"Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa","volume":"43","author":"Tao","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.101009_bib24","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0896-6273(95)90172-8","article-title":"Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture","volume":"15","author":"Meyer-Franke","year":"1995","journal-title":"Neuron"},{"key":"10.1016\/j.xops.2025.101009_bib25","first-page":"923","article-title":"Protective effects of ciliary neurotrophic factor on the retinal ganglion cells by injure of hydrogen peroxide","volume":"11","author":"Wang","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.xops.2025.101009_bib26","doi-asserted-by":"crossref","first-page":"E4520","DOI":"10.1073\/pnas.1303604110","article-title":"CNTF-mediated protection of photoreceptors requires initial activation of the cytokine receptor gp130 in M\u00fcller glial cells","volume":"110","author":"Rhee","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xops.2025.101009_bib27","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ophtha.2018.09.041","article-title":"Effect of ciliary neurotrophic factor on retinal neurodegeneration in patients with macular telangiectasia type 2: a randomized clinical trial","volume":"126","author":"Chew","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.101009_bib28","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400481","article-title":"Cell-based ciliary neurotrophic factor therapy for macular telangiectasia type 2","volume":"4","author":"Chew","year":"2025","journal-title":"NEJM Evid"},{"key":"10.1016\/j.xops.2025.101009_bib29","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.ajo.2014.12.013","article-title":"Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial","volume":"159","author":"Chew","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2025.101009_bib30","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1517\/14712598.6.7.717","article-title":"Application of encapsulated cell technology for retinal degenerative diseases","volume":"6","author":"Tao","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.xops.2025.101009_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1167\/iovs.66.11.3","article-title":"Long-term durability of ciliary neurotrophic factor-releasing revakinagene taroretcel-lwey in individuals with retinal degenerative disorders","volume":"66","author":"Kauper","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.101009_bib32","doi-asserted-by":"crossref","first-page":"Bio291","DOI":"10.1167\/iovs.17-21834","article-title":"Correlation between macular integrity assessment and optical coherence tomography imaging of ellipsoid zone in macular telangiectasia type 2","volume":"58","author":"Mukherjee","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.101009_bib33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1167\/tvst.9.4.27","article-title":"Longitudinal assessment of remnant foveal cone structure in a case series of early macular telangiectasia type 2","volume":"9","author":"Litts","year":"2020","journal-title":"Transl Vis Sci Technol"},{"issue":"Suppl 1","key":"10.1016\/j.xops.2025.101009_bib34","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/IAE.0000000000001706","article-title":"Correlation of structural and functional outcome measures in a phase one trial of ciliary neurotrophic factor in type 2 idiopathic macular telangiectasia","volume":"38","author":"Sallo","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.xops.2025.101009_bib35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ajo.2024.02.021","article-title":"Drug approval for the treatment of geographic atrophy: how we got here and where we need to go","volume":"263","author":"Csaky","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"Suppl 1","key":"10.1016\/j.xops.2025.101009_bib36","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1097\/IAE.0000000000001697","article-title":"Correlation of clinical and structural progression with visual acuity loss in macular telangiectasia type 2: MacTel project report no. 6-The MacTel research group","volume":"38","author":"Peto","year":"2018","journal-title":"Retina"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914525003070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914525003070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:49:50Z","timestamp":1773920990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914525003070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2666914525003070"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2025.101009","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results from a Phase I Extension Study of Ciliary Neurotrophic Factor in Patients with Macular Telangiectasia Type 2","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2025.101009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"101009"}}